# US 2026/0091043 A1 · Compositions and methods for treating mycobacterium infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091043 A1
- Document ID: US20260091043A1
- Status: Published application
- Kind: A1
- Application number: 19/113,756
- Filed: 2023-09-20
- Published: 2026-04-02
- Earliest claimed: 2022-09-21
- Applicants: Data2Discovery, Inc.
- Inventors: John David WILD; Jeremy Joseph YANG; Sean EKINS
- Web page: https://patentgrep.com/patent/US20260091043A1

## CPC

- A61K 31/609: Amides, e.g. salicylamide {(labetalol, metoclopramide A61K31/166)}
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are treatments of infections and diseases caused by pathogenic bacteria, including the treatment of infections and diseases caused by Mycobactertaceae.

## Claims

### Claim 1

A composition comprising a salicylanilide or a prodrug thereof, or a hydrate or solvate of any of the foregoing, or a salt of the foregoing, for use in treating an infection caused at least in part by Mycobacteriaceae.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the Mycobacteriaceae include Mycobacterium tuberculosis complex (MTBC), Mycobacterium abscessus complex (MABC), Mycobacterium avium complex (MAC), Mycobacteria causing leprosy, Mycobacteria comorbid with cystic fibrosis, or M. ulcerans, or any combination of the foregoing.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the Mycobacteriaceae include Mycobacterium tuberculosis complex (MTBC).

### Claim 4 (depends on 1)

The composition of claim 1 wherein the Mycobacteriaceae include Mycobacterium abscessus complex (MABC).

### Claim 5 (depends on 1)

The composition of claim 1 wherein the Mycobacteriaceae include Mycobacterium avium complex (MAC).

### Claim 6 (depends on 1)

The composition of claim 1 wherein the Mycobacteriaceae include Mycobacteria causing leprosy.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the Mycobacteriaceae include Mycobacteria comorbid with cystic fibrosis, such as M. chitae or M. fallax, or a combination thereof.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the composition is configured for oral administration.

### Claim 9 (depends on 1)

The composition of claim 1 wherein the composition is configured for administration by inhalation.

### Claim 10 (depends on 1)

The composition of claim 1 wherein the host animal is a mammal, such as livestock, a companion animal, or a human.

### Claim 11 (depends on 1)

The composition of claim 1 wherein the host animal is immunocompromised.

### Claim 12 (depends on 1)

The composition of claim 1 wherein the salicylanilide is selected from the formula
and prodrugs thereof; and salts of any of the foregoing; where
RAr represents one or more aryl substituents;
RN is H, alkyl, or acyl; and
Ar is an optionally substituted aryl group or heteroaryl group.

### Claim 13 (depends on 12)

The composition of claim 12 wherein RArr is one or more halo groups, hydroxy, amino, or heteroaryl, or any combination of the foregoing.

### Claim 14 (depends on 1)

The composition of claim 1 wherein Ar is phenyl or substituted phenyl.

### Claim 15 (depends on 12)

The composition of claim 12 wherein RN is H.

### Claim 16 (depends on 12)

The composition of claim 12 wherein the prodrug is an 2-O-acyl derivative.

### Claim 17 (depends on 12)

The composition of claim 12 wherein the compound is selected from the formulae
where R1 is 5-Cl and R2 is 4-Cl, R1 is 5-Cl and R2 is c-Cl, or R1 is 5-Cl and R2 is 4-Br.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1 to 11 wherein the composition comprises salicylanilide, niclosamide, oxyclozanide, rafoxanide, closantel, 5-chlorosalicylanilide (CSA), 4′-bromosalicylanilide (BSA), 5-bromo-4′-chlorosalicylanilide (BCSA), 3,3′4′,5-tetrachlorosalicylanilide (TCSA), bromochlorosalicylanilide, 5-bromo-N-(3,5-dichlorophenyl)-2-hydroxy-benzamide, 5-chloro-N-(2,4-difluorophenyl)-2-hydroxy-benzamide, 3,5-dichloro-N-(2,4-difluorophenyl)-4-pyrrol-1-yl-benzamide, 4-amino-3,5-dichloro-N-(3,5-dichlorophenyl)benzamide, 5-chloro-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-benzamide, clioxanide, or any combination thereof.

### Claim 19 (depends on 1)

The composition of claim 1 wherein the composition comprises dibromsalan (DBS), metabromsalan (MBS), tribromsalan (TBS, 3,5,4′-tribromosalicylanilide), resorantel, 4′,5-dibromosalicylanilide or a combination thereof.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A method for treating a Mycobacteriaceae infection in a host animal, the method comprising administering a therapeutically effective amount of the composition of claim 1, or a unit dose comprising the composition of claim 1, in single or divided form, to the host animal.

### Claim 22

(canceled)
